Key result
Super-selective beta-blockers are safe in CVD with metabolic syndrome and T2D but are often underdosed.
Super-selective beta-blockers, particularly metoprolol tartrate, are safe and effective for cardiovascular disease management even in patients with metabolic syndrome or type 2 diabetes, and should be prescribed at recommended therapeutic doses.
Supports safe use of super-selective beta-blockers in diabetes and metabolic syndrome; leaves open optimal dosing in randomized trials.
The article provides a review of the topical issues of beta-blockers use in the clinical practice. Attention of practitioners is drawn to the possibility of using these or other beta-blockers in various clinical situations. Some beta-blockers, especially non-selective ones, have negative effects and cannot be used in certain clinical situations (metabolic syndrome, type 2 diabetes mellitus). Modern super-selective beta-blockers do not have these negative effects and can be widely used in clinical practice, including metabolic syndrome and type 2 diabetes. The review focuses on metoprolol tartrate, which has the most extensive evidence base for efficient treatment of various cardiovascular diseases. Another problem related to beta-blockers is their infrequent use or use at inadequate doses. In this connection, a practitioner should prescribe them at the recommended therapeutic doses in various clinical situations, according to the instructions for use of the drug.
No takes yet. Share an insight, caveat, or question.
D. V. Nebieridze (2018) conducted a review in Cardiovascular diseases, metabolic syndrome, type 2 diabetes mellitus. Beta-blockers (metoprolol tartrate) was evaluated. Modern super-selective beta-blockers, particularly metoprolol tartrate, can be safely used in cardiovascular diseases including metabolic syndrome and type 2 diabetes, but are often underdosed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: